VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2026 Earnings Call Transcript
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2026 Earnings Call Transcript November 13, 2025VistaGen Therapeutics, Inc. misses on earnings expectations.
Vistagen Therapeutics Inc. (VTGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 3,060,000 | $10,863,000 | 0.26% | |
| 2. | StemPoint Capital Michelle Ross | 2,488,685 | $7,749,263 | +4% | 1.55% |
| 3. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 1,978,492 | $7,023,647 | 0.24% | |
| 4. | Commodore Capital Egen Atkinson And Michael Kramarz | 1,575,000 | $5,591,250 | 0.27% | |
| 5. | Ikarian Capital Neil Shahrestani | 620,869 | $2,204,084 | +4% | 0.22% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.15 | 775,756 | $17,961,078.67 | 1,575,000 | 2023-08-07 | Filing | |
| $0.18 | 100,000 | $17,870.00 | 100,000 | 2022-08-18 | Filing | |
| $0.18 | 100,000 | $17,870.00 | 100,000 | 2022-08-18 | Filing | |
| $0.17 | 300,000 | $50,910.00 | 334,629 | 2022-08-17 | Filing | |
| $0.17 | 600,000 | $103,200.00 | 626,234 | 2022-08-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.89 | 60,000 | $53,400.00 | 20,637,286 | 2022-07-12 | Filing | |
| $3.13 | 30,000 | $93,750.00 | 72,786 | 2021-09-07 | Filing | |
| $0.00 | 4,982,103 | $0.00 | 17,897 | 2011-05-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,165,767 | $14,746,815 | 0.01% | |
| 2. | 2,676,580 | $9,501,859 | 0.47% | |
| 3. | 1,687,735 | $5,991,460 | 0% | |
| 4. | 423,128 | $1,502,105 | 0% | |
| 5. | 302,683 | $1,074,525 | 0% |
News See All
Vistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety Trial
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is a late clinical-stage biopharmaceutical company developing neuroscience-focused therapies, including innovative intranasal pherine compounds.
13 Best Psychedelic Stocks to Invest in Now
Unlike drugs such as cocaine or marijuana, psychedelics create an “alternate reality” by altering feelings, thoughts, and energy levels.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2026 Earnings Call Transcript
Operator: Good day, everyone, and thank you for standing by. Welcome to Vistagen Therapeutics Fiscal Year 2026 First Quarter Corporate Update Conference Call and Webcast.
Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is among the best growth stocks to invest in for the next 5 years. Analysts at Stifel reiterated their Buy rating on Vistagen Therapeutics, Inc.
15 Best Growth Stocks to Invest in for the Next 5 Years
Before making any decision, whether big or small, we instinctively weigh its long-term impact, and this is particularly true in the case of stocks.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call Transcript
Operator: Good day, everyone, and thank you for standing by. Welcome to the Vistagen Therapeutics Fiscal Year-End 2025 Corporate Update Conference Call and Webcast.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript
Operator: And good day. Thank you for standing by. Welcome to VistaGen Therapeutics Third Quarter Fiscal Year 2025 Corporate Update Conference Call.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Vistagen Therapeutics Fiscal Year 2025 Second Quarter Corporate Update Conference Call.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, greetings and welcome to Vistagen Therapeutics Fiscal Year 2025 First Quarter Corporate Update Conference Call.